Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.81 USD | +4.52% |
|
-1.38% | 0.00% |
04-15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
04-15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 454.8 | - | - |
Enterprise Value (EV) 1 | 454.8 | 454.8 | 454.8 |
P/E ratio | -6.36 x | -7.43 x | -9.34 x |
Yield | - | - | - |
Capitalization / Revenue | - | 67.6 x | 8.77 x |
EV / Revenue | - | 67.6 x | 8.77 x |
EV / EBITDA | -6.85 x | -6.91 x | -6.19 x |
EV / FCF | -10.8 x | -7.22 x | -14.7 x |
FCF Yield | -9.24% | -13.9% | -6.82% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 25,534 | - | - |
Reference price 2 | 17.81 | 17.81 | 17.81 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | 6.725 | 51.84 |
EBITDA 1 | - | -66.43 | -65.82 | -73.5 |
EBIT 1 | - | -63.8 | -82.03 | -40.64 |
Operating Margin | - | - | -1,219.72% | -78.39% |
Earnings before Tax (EBT) 1 | - | -48.14 | -76.89 | -39.89 |
Net income 1 | -69.97 | -52 | -66.27 | -53.81 |
Net margin | - | - | -985.37% | -103.79% |
EPS 2 | -7.220 | -2.800 | -2.398 | -1.906 |
Free Cash Flow 1 | - | -42 | -63 | -31 |
FCF margin | - | - | -936.73% | -59.8% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share 2 | - | - | - | - |
Announcement Date | 22/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA 1 | -16.08 | -16.13 | -16.4 | -17.91 | - | - |
EBIT 1 | -16.09 | -15 | -16.11 | -16.59 | -15 | -19 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -16.65 | -11 | -11.03 | -9.456 | -13.81 | -17.9 |
Net income 1 | -16.65 | -12.07 | -12.04 | -11.21 | -13.81 | -17.9 |
Net margin | - | - | - | - | - | - |
EPS 2 | -3.530 | -0.4737 | -0.4592 | -0.4278 | -0.5350 | -0.7550 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 08/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -42 | -63 | -31 |
ROE (net income / shareholders' equity) | - | -22.6% | -11% | -0.51% |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 0.02 | 0.02 | - |
Capex / Sales | - | - | 0.24% | - |
Announcement Date | 22/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 455M | |
+16.13% | 122B | |
+19.65% | 113B | |
+19.01% | 26.49B | |
-23.84% | 19.4B | |
-18.07% | 16.24B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- LENZ Stock
- Financials LENZ Therapeutics, Inc.